Advertisement
Advertisement
VRDN
Viridian Therapeutics, Inc. Common Stock
29.23
USDSponsored
+0.06
+0.21%
Feb 06, 15:59 UTC -5
Closed
After-Market
29.24
+0.01
+0.03%
VRDN Earnings Reports
Positive Surprise Ratio
VRDN beat 22 of 38 last estimates.
58%
Next Report
Date of Next Report
Mar 05, 2026
Estimate for Q4 25 (Revenue/ EPS)
$12.99M
/-$1.10
Implied change from Q3 25 (Revenue/ EPS)
-81.60%
/+223.53%
Implied change from Q4 24 (Revenue/ EPS)
+17935.91%
/+10.00%
Viridian Therapeutics, Inc. Common Stock earnings per share and revenue
On Nov 05, 2025, VRDN reported earnings of -0.34 USD per share (EPS) for Q3 25, beating the estimate of -1.10 USD, resulting in a 69.21% surprise. Revenue reached 70.57 million, compared to an expected 34.59 thousand, with a 203930.30% difference. The market reacted with a +8.29% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 17 analysts forecast an EPS of -1.10 USD, with revenue projected to reach 12.99 million USD, implying an increase of 223.53% EPS, and decrease of -81.60% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
FAQ
What were Viridian Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Viridian Therapeutics, Inc. Common Stock reported EPS of -$0.34, beating estimates by 69.21%, and revenue of $70.57M, 203930.3% above expectations.
How did the market react to Viridian Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 8.29%, changed from $22.55 before the earnings release to $24.42 the day after.
When is Viridian Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 05, 2026.
What are the forecasts for Viridian Therapeutics, Inc. Common Stock's next earnings report?
Based on 17
analysts, Viridian Therapeutics, Inc. Common Stock is expected to report EPS of -$1.10 and revenue of $12.99M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement